ImmunoCellular Financial Statements From 2010 to 2025
ImmunoCellular Therapeutics financial statements provide useful quarterly and yearly information to potential ImmunoCellular Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on ImmunoCellular Therapeutics financial statements helps investors assess ImmunoCellular Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ImmunoCellular Therapeutics' valuation are summarized below:ImmunoCellular Therapeutics does not presently have any fundamental trends for analysis.
This module can also supplement various ImmunoCellular Therapeutics Technical models . Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Check ImmunoCellular Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmunoCellular Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . ImmunoCellular financial statements analysis is a perfect complement when working with ImmunoCellular Therapeutics Valuation or Volatility modules.
ImmunoCellular |
ImmunoCellular Therapeutics Company Current Valuation Analysis
ImmunoCellular Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ImmunoCellular Therapeutics Current Valuation | (1.69 M) |
Most of ImmunoCellular Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmunoCellular Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, ImmunoCellular Therapeutics has a Current Valuation of (1.69 Million). This is 100.01% lower than that of the Biotechnology sector and 100.04% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.01% higher than that of the company.
ImmunoCellular Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ImmunoCellular Therapeutics's current stock value. Our valuation model uses many indicators to compare ImmunoCellular Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ImmunoCellular Therapeutics competition to find correlations between indicators driving ImmunoCellular Therapeutics's intrinsic value. More Info.ImmunoCellular Therapeutics is rated fourth overall in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value ImmunoCellular Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ImmunoCellular Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |